Gene expression profiling in acute allograft rejection: Challenging the immunologic constant of rejection hypothesis

Tara L. Spivey, Lorenzo Uccellini, Maria L. Ascierto, Gabriele Zoppoli, Valeria De Giorgi, Lucia G. Delogu, Alyson M. Engle, Jaime M. Thomas, Ena Wang, Francesco M. Marincola*, Davide Bedognetti

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

82 Scopus citations

Abstract

In humans, the role and relationship between molecular pathways that lead to tissue destruction during acute allograft rejection are not fully understood. Based on studies conducted in humans, we recently hypothesized that different immune-mediated tissue destruction processes (i.e. cancer, infection, autoimmunity) share common convergent final mechanisms. We called this phenomenon the "Immunologic Constant of Rejection (ICR)." The elements of the ICR include molecular pathways that are consistently described through different immune-mediated tissue destruction processes and demonstrate the activation of interferon-stimulated genes (ISGs), the recruitment of cytotoxic immune cells (primarily through CXCR3/CCR5 ligand pathways), and the activation of immune effector function genes (IEF genes; granzymes A/B, perforin, etc.).Here, we challenge the ICR hypothesis by using a meta-analytical approach and systematically reviewing microarray studies evaluating gene expression on tissue biopsies during acute allograft rejection. We found the pillars of the ICR consistently present among the studies reviewed, despite implicit heterogeneity.Additionally, we provide a descriptive mechanistic overview of acute allograft rejection by describing those molecular pathways most frequently encountered and thereby thought to be most significant. The biological role of the following molecular pathways is described: IFN-γ, CXCR3/CCR5 ligand, IEF genes, TNF-α, IL-10, IRF-1/STAT-1, and complement pathways. The role of NK cell, B cell and T-regulatory cell signatures are also addressed.

Original languageEnglish (US)
Article number174
JournalJournal of Translational Medicine
Volume9
Issue number1
DOIs
StatePublished - Oct 12 2011
Externally publishedYes

Funding

Tara Spivey’s research fellowship was made possible through the Clinical Research Training Program, a public-private partnership supported jointly by the NIH and Pfizer Inc. (via a grant to the foundation for NIH from Pfizer Inc.). Davide Bedognetti is a participant in the NIH Graduate Partnership Program and a graduate student at University of Genoa. Davide Bedognetti’s fellowship is supported by the Conquer Cancer Foundation of the American Society of Clinical Oncology (2011 Young Investigator Award). Davide Bedognetti thanks Dr. Pietro Blandini (U.C. Sampdoria, Genoa, Italy) for his useful suggestion on multidimensional data analysis.

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Gene expression profiling in acute allograft rejection: Challenging the immunologic constant of rejection hypothesis'. Together they form a unique fingerprint.

Cite this